These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6909038)

  • 1. The costs of cancer: a challenge to health care providers.
    McNaull FW
    Cancer Nurs; 1981 Jun; 4(3):207-12. PubMed ID: 6909038
    [No Abstract]   [Full Text] [Related]  

  • 2. Issues of payment for cancer care.
    Hoffman RW
    Prog Clin Biol Res; 1983; 132E():383-6. PubMed ID: 6647478
    [No Abstract]   [Full Text] [Related]  

  • 3. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health insurance coverage and cost barriers to needed medical care among U.S. adult cancer survivors age<65 years.
    Sabatino SA; Coates RJ; Uhler RJ; Alley LG; Pollack LA
    Cancer; 2006 Jun; 106(11):2466-75. PubMed ID: 16639732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can health care costs be contained? Yes, says one third party fiscal intermediary.
    Kaplan SX
    Empl Benefits J; 1978; 3(4):10-3, 15. PubMed ID: 10294880
    [No Abstract]   [Full Text] [Related]  

  • 6. Analyzing health care operations using ABC.
    Ross TK
    J Health Care Finance; 2004; 30(3):1-20. PubMed ID: 15151193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling health care costs through commercial insurance companies.
    Holzgraefe JR
    Duke Law J; 1978 May; (2):728-52. PubMed ID: 10239069
    [No Abstract]   [Full Text] [Related]  

  • 8. Incentive reimbursement as an impetus to cost containment.
    McCarthy C
    Inquiry; 1975 Dec; 12(4):320-9. PubMed ID: 128526
    [No Abstract]   [Full Text] [Related]  

  • 9. Is a paradigm shift in US healthcare reimbursement inevitable?
    Watanabe AM; Dollens RW; Malatestinic WN; Browne RA
    Circulation; 2004 Mar; 109(12):1456-9. PubMed ID: 15051649
    [No Abstract]   [Full Text] [Related]  

  • 10. The Blues' blitz on health care costs.
    Demkovich LE
    Natl J (Wash); 1979 Jun; 11(22):902-6. PubMed ID: 10241583
    [No Abstract]   [Full Text] [Related]  

  • 11. Critical appraisal of the DRG system. Problem areas for DRG reimbursement in the U.S.A.
    Harper DL
    Aust Health Rev; 1985; 8(1):14-21. PubMed ID: 10311188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic cost analysis in cancer management and its relevance today.
    Sharma K; Das S; Mukhopadhyay A; Rath GK; Mohanti BK
    Indian J Cancer; 2009; 46(3):184-9. PubMed ID: 19574668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplementary health insurance and cost-consciousness strategy.
    Seidman LS
    J Risk Insur; 1978 Jun; 45(2):291-310. PubMed ID: 10307672
    [No Abstract]   [Full Text] [Related]  

  • 14. Reimbursement of drug cost-medical assistance program.
    Hosp Formul; 1975 Mar; 10(3):120, 122, 142. PubMed ID: 10297178
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer insurance policies in Japan and the United States.
    Bennett CL; Weinberg PD; Lieberman JJ
    West J Med; 1998 Jan; 168(1):17-22. PubMed ID: 9448483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.
    J Natl Cancer Inst Monogr; 1998; (24):1-28. PubMed ID: 9704318
    [No Abstract]   [Full Text] [Related]  

  • 17. "Catastrophic" coverage: proponents of national health insurance may settle for that.
    Witherspoon WR
    Barrons; 1979 Mar; 59(11):11, 16, 18. PubMed ID: 10240788
    [No Abstract]   [Full Text] [Related]  

  • 18. The costs of cancer to a major employer in the United States: a case-control analysis.
    Barnett A; Birnbaum H; Cremieux PY; Fendrick AM; Slavin M
    Am J Manag Care; 2000 Nov; 6(11):1243-51. PubMed ID: 11185849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 20. Health care reform: focus on prevention would help decrease costs associated with ESRD.
    Kaufer S
    Nephrol News Issues; 1994 Jul; 8(7):10-1. PubMed ID: 8047172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.